METHOD

In this section, the data obtained from the clinical study of the study are examined and information about the method of the study is included. In addition, the data obtained through access to information systems are tested with various statistical methods.

Model of the Research

Aimed to examine the relationships of 87 participants, 50 patients and 37 control groups, according to their groups. There are no limitations in the research.

Data Collection Tool and Techniques

The data were collected by the relevant researcher through a clinical study, transferred to the Microsoft Excel program, organized, cleaned and made suitable for analysis. Roc Curve Analysis, Mann Whitney U, T Test, Paired T Test, Wilcoxon Test and Spearman Correlation Tests were used. Data analysis have been tested through IBM SPSS Statistics 26.0 (Statistical Package for social Science) package programs.

1. *ANALYZES*

Table 1: Frequency Distributions

	N (%)
Group	
Control	37 (42.5)
Patient	50 (57.5)
CODE	
TO	40 (46)
E+N	47 (54)
**VD	
one	46 (52.9)
2	24 (27.6)
3	13 (14.9)
4	4 (4.6)
***TE	
0	51 (58.6)
one	26 (29.9)
2	8 (9.2)
3	2 (2.3)

While 57.5% of the sample included in the analyzes were patients and 42.5% were the control group, E+N was used in 54% of the sample and E was used in 46%. 53% of the sample had ** vd level of 1 while parity level of 58.6% was 0.

Table 2: Kolmogorov Smirnov Normality Tests

	Total	Control	Patient
AGE	0.130	0.197	0.180
AGE (HFT)	0.200	0.200	0.066
**S	0.020*	0.200	0.014*
1.ST *S	0.200	0.008*	0.200
2.ST *S	0.200	0.056	0.200
**L	0.066	0.200	0.016*
*DL	0.097	0.200	0.010*
**SPINDLE	0,000*	0.016*	0.001*
N**	0.018*	0.200	0.030*
*BP	0,000*	0.001*	0,000*
D**	0,000*	0.003*	0,000*
previous B**	0.006*	0.033*	0.015*
recent B**	0.053	0.050	0.200
WHAT*	0.004*	0.028*	0.187
Ins ****	0.034*	0.181	0.170
End *******	0,000*	0,000*	0.001*

*Statistically significant at the 0.05 level.

In the normality test applied to the variables both in general and in groups, AGE, AGE (HFT), 1.ST *Ş, 2.ST *Ş, **L, *DL and current B** were normally distributed in the general data (p>0.05).) other variables were not normally distributed (p<0.05).

While AGE, AGE (HFT), 1.ST *S, 2.ST *S, H*** I*, Ins **** and current B** were normally distributed in the patient group (p>0.05), the other variables were normal. It was determined that it did not disperse (p<0.05).

In the control group, AGE, AGE (HFT), AK*, 2.ST *Ş, **L, *DL, H**, Ins **** and current B** variables It was found that while it was normally distributed (p>0.05), other variables were not normally distributed (p<0.05).

According to these results, parametric tests were used in the analysis of normally distributed variables, and non-parametric tests were used in the analysis of non-normally distributed variables.

Table 3: Analysis of Clinical Characteristic Variables by Groups (Mean±SD / Median-Range)

	Control	Patient	Total	p
AGE **	30.57 ± 4.93 / 31-19	31.1 ± 4.73 / 31-17	30.87 ± 4.8 / 31-20	0.612
AGE (HFT) **	25.8 ± 1.49 / 25.86-5.57	26.21 ± 1.48 / 26.07-6	26.04 ± 1.49 / 26-6.57	0.197
*BP ***	110.27 ± 10.65 / 114-36	110.24 ± 7.38 / 110-30	110.25 ± 8.86 / 110-36	0.549
D** ***	69.89 ± 6.49 / 70-25	69.62 ± 5.62 / 70-20	69.74 ± 5.97 / 70-25	0.788
previous B** ***	24.75 ± 5.55/ 22.8-22.1	26.28 ± 4.08 / 25.3-17.36	25.63 ± 4.79 / 24.98-22.1	0.025*
recent B** **	27.41 ± 5.26 / 26.56-20.81	28.72 ± 4.26 / 28.18-19.94	28.16 ± 4.73 / 27.47-20.81	0.206

*Statistically significant at the 0.05 level. ** T Test *** MWU Test

There is only a significant difference in the previous B** value between the patient and control groups of clinical characteristic variables (p<0.05). The previous B** values of the patient group were significantly higher than the control group.

Table 4: Analysis of Biochemical Variables by Groups (Mean±SD / Median-Range)

	Control	Patient	Total	p
AK* ***	85.66 ± 6.22 / 85.6-24.2	97.25 ± 12.46 / 9	/ 91-72	0,000*
1.ST *S **	135.46 ± 31.35 / 146-111.3	197.83 ± 24.76 /	.3 / 175-187.6	0,000*
2.ST *S **	106.54 ± 20.24 / 102.7-78	157.8	± 36.38 / 135-180.5	0,000*
L	254.86 ± 48.99 / 257-206		243 ± 54.4 / 241-237	0.080
*DL**	144.24 ± 39.22 / 138-181.4		134.1 ± 42.86 / 126-215	0.057
IG *	169.08 ± 54.38 /	/ 176.5-491	186.16 ± 77.61 / 165-491	0.135
H** ***	74.4	8.99 ± 16.57 / 69-74	71.33 ± 16.34 / 70.9-83	0.085
WHAT* ***	2.6	4.13 ± 1.85 / 3.80-8.72	3.56 ± 1.84 / 3.18-8.78	0,000*
Ins **** ***	13.19 ±	17.06 ± 6.91 / 16.00-29.00	15.41 ± 7.07 / 14.00-29.00	0.007*
End ******** ***	72.5 ± 76	121.98 ± 104.08 / 115.72-404.51	100.94 ± 95.96 / 53.29-414.91	0.003*

*Statistically significant at the 0.05 level. ** T Test *** MWU Test

There are significant differences between the patient and control groups of biochemical variables that EC*, 1.ST *S, 2.ST *S, H*** I*, Ins **** and END****** (p <0.05). AK*, 1.ST *S, 2.ST *S, H*** I*, Ins **** and END****** values of the patient group were significantly higher than the control group.

*Table 5: Analysis by K** (Mean±SD / Median-Range)*

	TO	E+N	Total	p
AGE **	30.33 ± 5.2 / 29-20	31.34 ± 4.42 / 31-17	30.87 ± 4.8 / 31-20	0.328
AGE (HFT) **	26.02 ± 1.52 / 26-6.57	26.05 ± 1.48 / 26-5.71	26.04 ± 1.49 / 26-6.57	0.917
AK* ***	92.82 ± 12.6 / 91-70.2	91.9 ± 11.07 / 90.9-58	92.32 ± 11.74 / 91-72	0.825
1.ST *S **	174.27 ± 41.71 / 183.45-184.2	168.79 ± 41.61 / 172-187.6	171.31 ± 4 175-187.6	0.542
2.ST *S **	134.5 ± 37.36 / 130-165.8	137.44 ± 35.87 / 136.4-151.5	136 35-180.5	0.709
L	227.45 ± 45.91 / 221.5-191	256.24 ± 57.93 / 257-237	41-237	0.013*
*DL**	124.67 ± 37.59 / 117.5-134	142.13 ± 45.74 / 13	26-215	0.058
IG *	174.13 ± 66.88 / 160-300	196.4 ± 85	7.61 / 165-491	0.215
H** ***	67.58 ± 16.06 / 66-63		71.33 ± 16.34 / 70.9-83	0.036*
*BP ***	111.18 ± 8.52 / 110-36		110.25 ± 8.86 / 110-36	0.400
D** ***	70.93 ± 6.01 /	70-20	69.74 ± 5.97 / 70-25	0.103
previous B** ***	25.81 ± 5.4	4.18 / 25-20.5	25.63 ± 4.79 / 24.98-22.1	0.929
recent B** **	28	4.26 / 27.18-20.37	28.16 ± 4.73 / 27.47-20.81	0.542
WHAT* ***		3.24 ± 1.81 / 2.96-6.52	3.35 ± 1.93 / 3.04-8.78	0.788
Ins **** ***	1	14.19 ± 7.51 / 13-27	14.55 ± 7.76 / 13-29	0.848
End ******** ***	124.11 ± 10	81.22 ± 80.13 / 36.5-312.39	100.94 ± 95.96 / 53.29-414.91	0.044*

*Statistically significant at the 0.05 level. ** T Test *** MWU Test

There is a significant difference only in **L, H** and END******* values according to the use of K** (p<0.05). While **L and H** values of those who used EK**i were significantly lower than those who used EK**i, END****** values of those who used EK**i were significantly higher.

*Table 6: Analysis by K** in the Control Group (Mean±SD / Median-Range))*

	TO	E+N	Total	p
AGE **	30.14 ± 5.72 / 28.5-19	30.83 ± 4.5 / 31-17	30.57 ± 4.93 / 31-19	0.689
AGE (HFT) **	25.65 ± 1.48 / 25.93-4.57	25.88 ± 1.52 / 25.86-5.29	25.8 .86-5.57	0.657
AK* **	83.87 ± 5.33 / 84.7-18.7	86.76 ± 6.57 / 86.9-20.2	6-24.2	0.174
1.ST *S***	132.51 ± 32.9 / 143.05-102.4	137.26 ± 30.98 / 146.1-11	111.3	0.594
2.ST *S **	98.59 ± 13.19 / 95.6-41.5	111.37 ± 22	102.7-78	0.036*
L	234.14 ± 37.14 / 225-138	267.4	48.99 / 257-206	0.043*
*DL**	131.91 ± 33.16 / 122-122.8		44.24 ± 39.22 / 138-181.4	0.138
IG *	153.29 ± 54.17 / 144.5	173	169.08 ± 54.38 / 159-204	0.129
H** **	70.71 ± 16	15.2 / 73-72	74.49 ± 15.7 / 72-72	0.260
*BP ***	110.86	91 ± 10.27 / 110-35	110.27 ± 10.65 / 114-36	0.681
D** ***		69.7 ± 5.94 / 70-20	69.89 ± 6.49 / 70-25	0.809
previous B** ***	2	25.98 ± 5.31 / 25.4-20.5	24.75 ± 5.55/ 22.8-22.1	0.018*
recent B** **	25.5	28.55 ± 5/27.47-20.37	27.41 ± 5.26 / 26.56-20.81	0.092
WHAT* ***	2.55 ± 1.43 / 2.07-4.91	3.59 ± 1.91 / 3.04-6.52	3.2 ± 1.8 / 2.85-6.55	0.067
Ins **** ***	12.21 ± 6.34 / 9.5-22	16.74 ± 8.43 / 15-27	15.03 ± 7.93 / 14-27	0.082
End ******** ***	95.11 ± 104 / 38.03-266.23	58.73 ± 50.86 / 29.16-160.42	72.5 ± 76.2 / 29.16-269.96	0.707

*Statistically significant at the 0.05 level. ** T Test *** MWU Test

In the control group, there was only a significant difference in the 2.ST *S, **L and previous B** values compared to the use of C** (p<0.05). 2.ST *S, **L and previous B** values of those who used EK**i were significantly lower than those who used E+N.

*Table 7: Analysis by K** in the Patient Group (Mean±SD / Median-Range))*

	TO	Y+N	Total	p
AGE **	30.42 ± 5.01 / 29.5-16	31.83 ± 4.39 / 31.5-14	31.1 ± 4.73 / 31-17	0.297
AGE (HFT) **	26.21 ± 1.53 / 26.14-6	26.21 ± 1.46 / 26-5.29	26.21 ± 1.48 / 26.07-6	1,000
AK* ***	97.63 ± 12.81 / 95.4-69	96.84 ± 12.33 / 96.35-58	97.25 ± [illegible] / 96-72	0.915
1.ST *S **	196.75 ± 25.48 / 194.5-122	199 ± 24.46 / 190.95-96.5	197.8[illegible] [illegible]5-123	0.752
2.ST *S **	153.83 ± 31.24 / 153.55-137	162.43 ± 27.6 / 158.4-100.3	[illegible]-137	0.309
L*	223.85 ± 50.32 / 211.5-191	245.47 ± 62.52 / 232.5-[illegible]	[illegible]-234	0.156
*DL***	120.77 ± 39.84 / 112-134	132.92 ± 48.65 / [illegible]	[illegible]25/115.5-215	0.183
IG *	185.35 ± 71.26 / 169-300	213.37 ± [illegible]	[illegible] ± 89.54 / 176.5-491	0.420
H** ***	65.88 ± 15.97 / 64.5-61	[illegible]	68.99 ± 16.57 / 69-74	0.145
*BP ***	111.35 ± 6.57 / 110-[illegible]	[illegible]30	110.24 ± 7.38 / 110-30	0.318
D** ***	71.31 ± 5[illegible]	[illegible].64 / 70-20	69.62 ± 5.62 / 70-20	0.028*
previous B** ***	27.46 ± [illegible]	[illegible] ± 2.75 / 24.98-11.9	26.28 ± 4.08 / 25.3-17.36	0.062
recent B** **	30.09 ± [illegible]	27.23 ± 3.4 / 27.09-13.69	28.72 ± 4.26 / 28.18-19.94	0.016*
WHAT* ***	3.97 [illegible].6	2.90 ± 1.69 / 2.78-6.24	3.46 ± 2.04 / 3.1-8.72	0.082
Ins **** ***	16.46 [illegible].68 / 14-29	11.75 ± 5.67 / 11.5-23	14.2 ± 7.69 / 12.5-29	0.077
End ******** ***	139.73 ± 109.21 / 122.43-402.73	102.76 ± 96.83 / 43.44-301.99	121.98 ± 104.08 / 115.72-404.51	0.091

*Statistically significant at the 0.05 level. ** T Test *** MWU Test

In the patient group, only D** and current B** values were significantly different according to the use of K** ($p<0.05$). D** and current B** values of those who used EK**i were significantly higher than those who used E+N.

Paired Analyzes in Patient, Control, and Total Groups (Mean±SD / Median-Range)

	Control	Patient	Total
1.ST *S	135.46 ± 31.35 / 146.00-111.30	197.83 ± 24.76 / 193.50-123.00	171.31 ± 41.50 / 175.00-187.60
2.ST *S	106.54 ± 20.24 / 102.70-78.00	157.96 ± 29.57 / 156.00-137.00	136.09 ± 36.38 / 135.00-180.50
p	0.000 * ,W	0.000 * ,T	0.000 * ,T
previous B**	24.75 ± 5.55/22.80-22.10	26.28 ± 4.08 / 25.30-17.36	25.63 ± 4.79 / 24.98-22.10
recent B**	27.41 ± 5.26 / 26.56-20.81	28.72 ± 4.26 / 28.18-19.94	28.16 ± 4.73 / 27.47-20.81
p	0.000 * ,W	0.000 * ,W	0.000 * ,W

*Statistically significant at the 0.05 level. W Wilcoxon Test. T Paired T Test.

When the BG and B** values of the control, patient and Total groups were compared with the previous ones, a significant difference was found ($p<0.05$). 2.ST *Ş values are significantly lower than 1.ST *Ş values, while current B** values are significantly higher than the previous ones.

*Table 9: Relationship between End ******* Values and Variables - Spearman Correlation Analysis(r (p))*

	Control	Patient	Total
AGE	-0.25 (p=0.136)	0.04 (p=0.768)	-0.07 (p=0.544)
AGE (HFT)	0.04 (p=0.792)	0.12 (p=0.416)	(p=0.278)
WHITE*	-0.03 (p=0.844)	-0.02 (p=	=0.096)
1.ST *S	0.10 (p=0.555)		0.002*)
2.ST *S	0.01 (p=0.9		28 (p=0.010*)
**L	0.0		-0.01 (p=0.917)
*DL		(p=0.511)	-0.05 (p=0.678)
**SPINDLE		0.00 (p=0.990)	0.05 (p=0.656)
N**	.485)	0.17 (p=0.227)	-0.01 (p=0.896)
*BP	.25 (p=0.129)	-0.13 (p=0.369)	-0.19 (p=0.077)
D**	-0.25 (p=0.130)	-0.12 (p=0.410)	-0.17 (p=0.115)
previ	-0.15 (p=0.365)	0.07 (p=0.647)	0.00 (p=0.977)
recent	-0.16 (p=0.348)	-0.03 (p=0.843)	-0.05 (p=0.655)
WHAT*	-0.11 (p=0.512)	0.07 (p=0.634)	0.10 (p=0.374)
Ins ****	-0.12 (p=0.479)	0.10 (p=0.477)	0.08 (p=0.482)

*Statistically significant at the 0.05 level

Spearman correlation analysis between the End ******* values of the variables and both general and group distinctions , the End ******* values only showed a positive low level correlation with 1.ST *Ş and 2.ST *Ş in the general data. was found to be in a relationship ($p<0.05$).

*Table 10: The sensitivity , specificity of End *******

	End *******
cut-off	25.99
Sensitivity	88.0%
specificity	43.2%
accuracy	69.0%
Area Under the Curve (AUC)	0.688
95%CI	0.574-0.803

Youden Index maximization method was used in the ROC Curve Analysis to determine the End ******* levels that determine the patient group . According to this method;

88.0 % sensitivity and 43.2 % specificity , 25.99 and higher End ******* level cutoff values were determined.

*Figure 1 : End ******* Level ROC Curve Graph*